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ABSTRACT
Objective: Using electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with
synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complemen-
tary biomolecular data, including disease-specific gene expression and drug-protein interactions, provide
mechanistic understanding.
Method:We applied Group Lasso INTERaction NETwork (glinternet), an overlap group lasso penalty on a logis-
tic regression model, with pairwise interactions to identify variables and interacting drug pairs associated with
reduced 5-year mortality using EHRs of 9945 breast cancer patients. We identified differentially expressed
genes from 14 case-control human breast cancer gene expression datasets and integrated them with drug-
protein networks. Drugs in the network were scored according to their association with breast cancer individu-
ally or in pairs. Lastly, we determined whether synergistic drug pairs found in the EHRs were enriched among
synergistic drug pairs from gene-expression data using a method similar to gene set enrichment analysis.
Results: From EHRs, we discovered 3 drug-class pairs associated with lower mortality: anti-inflammatories and
hormone antagonists, anti-inflammatories and lipid modifiers, and lipid modifiers and obstructive airway drugs.
The first 2 pairs were also enriched among pairs discovered using gene expression data and are supported by
molecular interactions in drug-protein networks and preclinical and epidemiologic evidence.
Conclusions: This is a proof-of-concept study demonstrating that a combination of complementary data sour-
ces, such as EHRs and gene expression, can corroborate discoveries and provide mechanistic insight into drug
synergism for repurposing.
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Research and Applications
INTRODUCTION
Electronic health records (EHRs) reflect real-world treatment pat-
terns including polypharmacy, offering a unique opportunity to
study drug-associated outcomes for drug safety and repurposing ef-
forts.1–3 Molecular data, such as gene expression, and drug-protein
interactions offer possible mechanistic insight into drug-disease rela-
tionships.4 These 2 types of data strongly complement each other,
for example, in assessing the repurposing potential of existing drug
combinations. Prior studies have mainly focused on discovering ad-
verse effects of single or combined drugs (ie, drug-drug interac-
tions5,6) or repurposing single drugs,2,7–9 such as metformin for
breast cancer. Although there have been mixed results in replicating
metformin’s apparent anticancer benefit,1,10–15 preliminary results
from ongoing clinical trials16 appear promising.
Beyond repurposing individual drugs, combinations of drugs
may yield adjuvant therapeutic effects or allow lower doses to
achieve the same therapeutic effects while minimizing the undesir-
able side effects triggered at higher doses.17 Drugs can interact with
each other such that the bioavailability of one drug is increased or
prolonged (pharmacokinetic interaction) or the target receptor or
pathway is modulated to elicit a stronger therapeutic response
(pharmacodynamic interaction).18 Additionally, finding beneficial
combinations of approved or investigational drugs can save consid-
erable cost and time, because some safety assessments have already
been performed.7,19 Such multidrug synergism is currently discov-
ered experimentally through large-scale target screening20 and theo-
retically through reasoning based on known pharmacokinetic or
pharmacodynamic interactions.21
This study demonstrates the novel use of both EHRs and molec-
ular data to discover and validate pairs of drugs whose combined
therapeutic effect on mortality among breast cancer patients appears
to be greater than that of the individual drugs alone. Our approach
for eliciting beneficial pairs of drugs is a first step toward discover-
ing more complex multidrug combinations that can optimize the use
of existing drugs.
METHODS
Analysis of electronic health records
EHR data sources
We used Oncoshare,22 a breast cancer database linking long-term
survival outcomes from the California Cancer Registry with EHRs
detailing patient, tumor, and treatment information from a tertiary
cancer care center (Stanford Hospital) and a neighboring commu-
nity health system (Palo Alto Medical Foundation, PAMF). Onco-
share followed 14 885 female patients (at least 18 years old) with a
breast cancer diagnosis in the registry and sought treatment at Stan-
ford Hospital or PAMF between January 2000 and April 2013. To
determine 5-year mortality, we included only patients who were fol-
lowed for at least 5 years starting from the index date of breast can-
cer diagnosis or who died within the follow-up period. By excluding
patients who were followed <5 years (ie, diagnosed after April
2008), we minimized the loss to follow-up; this process was already
facilitated through statewide mortality tracking by the California
Cancer Registry. We extracted 1531 demographic, tumor (eg, stage,
hormone subtype), and treatment (eg, prescriptions, radiotherapy,
diagnostic imaging) variables. Data and methodological details on
Oncoshare can be found in Kurian et. al.22 Individual drugs were an-
alyzed as generic ingredients according to RxNORM23 as well as ag-
gregated into 95 drug classes according to the Anatomical
Therapeutic Chemical (ATC) system24 (Supplementary Table S1).
Demographic and tumor variables, if missing and comprising at
least 10% of the cohort, were coded as “unknown” and analyzed as
a separate category, or otherwise (if <10% were missing) replaced
by mode imputation (for categorical variables) or mean imputation
(for continuous variables).
To examine concomitant drug exposures, we set up a data matrix
in which each row is an exposure period for every unique drug combi-
nation (Figure 1A). This matrix contains 171 940 unique exposure pe-
riods derived from 9945 eligible patients. A cumulative exposure
variable measures the duration patients were exposed to that drug
combination during their follow-up time. Drugs and drug classes used
for fewer than 14 days (cumulative) or present in less than 0.5% of
the exposure periods were removed, leaving 294 drugs (Supplemen
tary Table S1) for analysis of 43 071 possible pairwise combinations.
Variables entered into the logistic regression included all demo-
graphic, tumor, and treatment variables. We examined for association
at both the individual drug level and the ATC drug class level.
Synergism score from EHR
To identify potentially interesting associations between 5-year mor-
tality and pairwise combinations between drugs and drug classes,
we used lasso25 regularization on a logistic regression model with
pairwise interactions (Equation 1). Drug interactions were modeled
as statistical interactions. Here, we used Group-Lasso INTERaction
NETwork26 (glinternet), an overlap group lasso designed to select a
pairwise interaction effect bi,j along with its constituting main effects
bi and bj.
log p
1 pð Þ ¼ b0 þ
X
bixi þ
X
bi;jxixj Equation 1
A main effect bi refers to the contribution of an independent vari-
able xi toward the response (log odds of 5-year mortality where p is
the probability of 5-year mortality) while ignoring all other indepen-
dent variables. An interaction effect bi,j arises when 2 independent
variables, xi and xj, influence each other’s contribution toward the
response. For example, although drug i and drug j are individually
associated with an outcome by bi and bi, respectively, when used to-
gether, they may modify each other’s contribution toward the re-
sponse such that the combined response (biþbiþbi,j) is not simply
the sum of their individual parts (biþbi).
An interaction effect is termed synergistically beneficial when the
combined effect is more negatively correlated with mortality than
the most negative association of individual drugs. An interaction ef-
fect is synergistically adverse when the combined effect is more posi-
tively associated with mortality than the maximum positive
association of individual drugs. An interaction may also be antago-
nistic when the combined effect is closer to null than either drug’s ef-
fect. Note that these terms describe the net association of the drug
combination relative to that of individual drugs instead of the sign
of the interaction coefficient.
Modeling implementation
Interactions involving categorical and continuous variables were
handled differently in the glinternet R package (version 3.1.0).26 For
each categorical variable (eg, tumor stage), all possible levels (0 to
IV, unknown) and their pairwise interactions with another variable
(eg, received zoledronate or not) were considered in a group lasso.26
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Figure 1. Method overview of (A) scoring EHR-based synergistic drug pairs, (B) scoring gene expression–based synergistic drug pairs, and (C) gene set enrich-
ment analysis–like analysis of enrichment of EHR-based drug class pairs among gene expression–based drug pairs.
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Modeling parameters were set to select up to 300 interaction terms
for computational tractability.
We set aside a 10% hold-out set for model validation and a 10%
tuning set for tuning the lasso penalty factor, k. After obtaining the
optimal k from the 10% tuning set by 3-fold cross-validation, we
trained the regression model on the full non–hold-out set. Finally,
trained models were then validated on the 10% hold-out set. All re-
ported performance measures (eg, sensitivity, specificity, area under
curve) were from validating the models in the hold-out set.
We generated 95% confidence intervals (CIs) for the beta coeffi-
cients of the regression model by bootstrapping 500 times, fitting a
regression model to each bootstrapped sample.27 Bootstrap resam-
pling was performed at the patient level instead of the exposure pe-
riod level to account for within-patient correlated periods. In other
words, patients were randomly sampled with replacement such that
all their exposure periods were also sampled together. Each boot-
strap sample also maintained the case-control ratio (at the patient
level) and had approximately the same number of periods as the
original training sample. This generated 500 different values for
each beta coefficient, where the 2.5th and 97.5th percentiles were
taken as the limits of the 95% CI.
Analysis of gene expression data
Molecular data sources
From ArrayExpress28 and Gene Expression Omnibus,29 14 gene ex-
pression datasets from breast tissue of patients matched to healthy
controls, or of tumor tissue matched to normal tissue within the
same patient, were appropriately formatted for use in the analysis
(Supplementary Table S2). Raw data were downloaded and normal-
ized using Robust Multi-array Average (RMA) (R package Affy)30
after low-quality samples were removed by ArrayQualityMetrics.31
When raw data were unavailable, processed data were used instead.
For microarray data, GeoDE32 was used to identify significant dif-
ferentially expressed genes. For RNA-seq data, raw reads were
downloaded and quality trimmed (trimGalore33), and transcripts
quantified (kallisto34). Default settings were used for all packages.
Breast cancer association score of drug pairs from gene expression
data
Differentially expressed genes were mapped to proteins using Uni-
Prot identifiers. Differentially expressed proteins in breast cancer,
drugs linked by drug-protein interactions (DPIs; DrugBank.ca
v4.035), and proteins linked by protein-protein interactions (PPIs;
Dr PIAS36) were integrated in a network (Figure 1B). Inclusion of
PPI data in this network captures potentially relevant drug-protein
relationships in which a drug’s direct interacting protein, or target,
may not itself be differentially expressed, but may have altered activ-
ity in breast cancer (eg, drug interacting with a transcriptional regu-
lator). Additionally, including PPI can improve the reproducibility
of molecular models of cancer.37,38 Drugs were scored according to:
(1) the number of proteins differentially expressed in breast cancer
with which that drug’s targets interact, (2) the confidence and direc-
tionality of those interactions, and (3) the consistency of differential
protein expression across individual breast cancer datasets. Higher
scores indicate increased molecular association with breast cancer
and potential therapeutic efficacy. After scoring drugs individually,
scores were assigned to over 10 million possible drug pairs. Synergis-
tically beneficial pairs were defined as those in which the union of
the 2 drugs’ protein interactions resulted in a higher association
score compared to the maximum of either drug’s individual score.
Scores for all nonsynergistic pairs were set to 0.
Enrichment of EHR-derived drug pairs among gene expression–
derived drug pairs
Using a method similar to gene set enrichment analysis (GSEA),39
we determined the enrichment of drug pairs coming from classes
identified as synergistically interacting from the EHR among the
highest scoring drug pairs identified using gene expression.
First, all synergistic drug pairs identified using gene expression
were ranked by their synergism score (Figure 1C, shaded area).
Then, starting with the highest ranked gene expression–derived drug
pair, a cumulative sum (Figure 1C, Enrichment score) was either in-
creased (if the pair consisted of drugs present in EHR-derived syner-
gistic class pairs) or decreased (if both drugs were not present in the
EHR-derived synergistic drug classes). The value added to the cumu-
lative sum was proportional to the drug pair’s breast cancer associa-
tion score, while the value subtracted was dependent on the number
of total drug pairs examined, such that the cumulative sum was nor-
malized between 1 and 1. For drug pairs with tied synergism
scores, the value computed for all tied pairs was added to or sub-
tracted from the cumulative sum at the first drug pair in the tie. Sub-
sequent pairs in the tie did not affect the cumulative sum.
A raw enrichment score was derived based on the maximum de-
viation of the cumulative sum from 0. To determine statistical signif-
icance, we obtained a median baseline from 10 000 bootstrap
samples of random drug pairs. A normalized enrichment score
(NES) ratio (ie, raw enrichment score divided by median baseline)
greater than 1 with low P value indicates significant enrichment.
RESULTS AND DISCUSSION
Study cohort
To discover synergistic drug combinations from EHRs, we used a fi-
nal study cohort (Table 1 and Figure 1A) consisting of 9945 patients
who either died within 5 years starting from the index date of breast
cancer diagnosis (1212 cases) or were followed for at least 5 years
(8733 controls).
Small values are stated as “<10” for privacy purposes, in accor-
dance with California Cancer Registry guidelines.
Main factors associated with survival from EHR
Comparing cases against controls, our logistic models, using 5-year
mortality as the binary response, achieved satisfactory classification
performance (90% area under the curve, 40% sensitivity, 99% spe-
cificity) on a 10% hold-out validation set.
Consistent with well-established breast cancer prognostic fac-
tors,40 the main factors associated with lower mortality identified in
our model (Figure 2 and Supplementary Table S3) are lower stage
and living in a neighborhood or census block in the top 20% of so-
cioeconomic status in California.41 In contrast, factors such as ad-
vanced stage, older age at diagnosis, and the triple-negative breast
cancer subtype were associated with higher mortality.
Synergistic interactions from EHRs
Variables that consistently formed synergistic interactions associated
with lower mortality (nodes with mostly blue edges, Figure 3) coin-
cided with the main effects associated with lower mortality de-
scribed above (eg, being diagnosed at a lower stage, having a higher
socioeconomic status). In contrast, variables that consistently
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Table 1. Patients who died within (cases) or survived (controls) 5 years of breast cancer diagnosis
Patient Characteristic Cases/Dead (n¼ 1212) Controls/Alive (n¼ 8733) Total (n¼ 9945)
N or mean % or SD N or mean % or SD N or mean % or SD
Agea
<40 121 10% 787 9% 908 9%
40–49 221 18% 2403 28% 2,624 26%
50–59 251 21% 2490 29% 2,741 28%
60–69 219 18% 1794 21% 2,013 20%
70 400 33% 1259 14% 1,659 17%
Year of diagnosis
2000–2003 334 28% 2988 34% 3,322 33%
2004–2006 366 30% 3222 37% 3,588 36%
2007–2009 402 33% 2523 29% 2,925 29%
2010–2011 110 9% 0 0% 110 1%
Race
White/unknown 997 82% 7109 81% 8,106 82%
Black 62 5% 192 2% 254 3%
Asian/Pacific islander 152 13% 1423 16% 1,575 16%
Native American <10 0.1% <10 0.1% <10 0.1%
Marrieda 661 55% 5813 67% 6,474 65%
Socioeconomic statusa
Lowest 20% 74 6% 266 3% 340 3%
21st–40th percentile 142 12% 607 7% 749 8%
41st–60th percentile 174 14% 975 11% 1,149 12%
61st–80th percentile 245 20% 1739 20% 1,984 20%
Top 20% 577 48% 5146 59% 5,723 58%
Hormone receptor subtype
ERþ only 98 8% 612 7% 710 7%
ERþ/PRþ and HER2þ 115 9% 819 9% 934 9%
HER2þ only 101 8% 362 4% 463 5%
PRþ only 420 35% 4406 50% 4,826 49%
TNBC 264 22% 589 7% 853 9%
Unknown 214 18% 1945 22% 2,159 22%
Stagea
Stage 0 49 4% 1736 20% 1,785 18%
Stage I 219 18% 3260 37% 3,479 35%
Stage II 351 29% 2576 29% 2,927 29%
Stage III 262 22% 548 6% 810 8%
Stage IV 252 21% 89 1% 341 3%
Unknown 79 7% 524 6% 603 6%
Gradea
Grade I 101 8% 1714 20% 1815 18%
Grade II 321 26% 3451 40% 3772 38%
Grade III 527 43% 2031 23% 2558 26%
Grade IV 43 4% 501 6% 544 5%
Unknown 220 18% 1036 12% 1256 13%
Ductal tumora 1,033 85% 7459 85% 8492 85%
Behavior of tumora
In situ 62 5% 2058 24% 2120 21%
Malignant 1150 95% 6675 76% 7825 79%
Bilaterala 1164 96% 8586 98% 9750 98%
Lymph vascular invasiona 35 3% <10 0.1% 41 0.4%
Comorbiditiesa
Myocardial infarction <10 0.7% 17 0.2% 26 0.3%
Congestive heart failure 15 1.2% 11 0.1% 26 0.3%
Peripheral vascular disease 26 2% 28 0.3% 54 0.5%
Cerebrovascular disease 34 3% 66 0.8% 100 1%
Dementia <10 0.1% <10 0.01% <10 0.02%
Chronic obstructive pulmonary disease 74 6% 215 2% 289 3%
Rheumatic disorders <10 0.6% 15 0.2% 22 0.2%
Peptic ulcer disease <10 0.0% <10 0.01% <10 0.01%
Liver, mild <10 0.7% <10 0.08% 16 0.2%
Liver, severe <10 0.5% <10 0.02% <10 0.08%
(continued)
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formed synergistic interactions associated with higher mortality
(nodes with mostly red edges, Figure 3) coincided with the main ef-
fects associated with higher mortality (eg, older age at diagnosis, ad-
vanced stage). In addition to patient and tumor characteristics that
synergistically influence mortality, we identified drug pairs that are
synergistically associated with lower mortality (Table 2 and Figure 3,
bold blue edges).
Subgroup analysis by molecular subtype
We analyzed synergistic variable interactions in patients stratified by
molecular subtype given their varied prognoses and drug utilizations
(Table 2 and Supplementary Figure S1). In the estrogen receptor or
progesterone receptor positive group, our model identified synergis-
tic pairs of antiestrogens or aromatase inhibitors with antiemetics
(eg, ondansetron, granisetron), possibly due to the increased toler-
ance afforded by the antiemetics.42 Among human epidermal
growth factor receptor 2–positive patients, who often have worse
prognoses than other hormone-sensitive subtypes, several synergistic
pairs included phenazopyridine, which might have been prescribed
to relieve urethral discomfort from aggressive estrogen suppression.
Rediscovering such coprescription patterns known to alleviate side
effects suggests that our approach can uncover beneficial combina-
tions. Note that while these combinations are associated with re-
duced mortality, causality cannot be determined.
Several synergistic interactions were replicated in the molecular
subtypes and the overall cohort. Lipid modifiers (C10, including sta-
tins, eg, simvastatin) paired with either anti-inflammatory agents
(M01, which includes nonsteroidal anti-inflammatory drugs
[NSAIDs], eg, naproxen) or drugs for obstructive airways (R03, eg,
fluticasone) reduced mortality both in the overall cohort and the
TNBC subtype group.
Synergistic drug pairs from gene expression data
In an orthogonal approach, we identified 8966 differentially ex-
pressed proteins from breast cancer gene expression data. These pro-
teins were than associated with 7686 drugs via a DPI database
(Drugbank35) These data were then used to construct a molecular
network. From this network, a synergistic breast cancer association
score was calculated for all possible pairs of drugs in the DPI data;
these were then ranked in descending order (see the shaded histo-
grams scaled to the right axis in Figures 4A and B).
Next we determined whether this gene expression approach
identified the same synergistic drug classes as the EHR (Table 2). To
do so, we used a GSEA-based enrichment method to quantify the en-
richment of EHR synergistic classes among gene expression syner-
gistic pairs.39 Figure 4A shows that the 528 drug pairs derived from
one pair of synergistic classes identified using EHR (anti-inflamma-
tories/antirheumatics paired with lipid modifiers, black bars) tended
to also be high-scoring gene expression–based drug pairs (shaded
histograms with scale on the right axis). Specifically, drug pairs de-
rived from these EHR-based classes were 4.4 times more enriched
among high-scoring gene expression–based pairs compared to
10 000 randomly selected sets of 528 drug pairs (P<0.0001). In
Figure 4B, anti-inflammatories/antirheumatics paired with hormone
antagonists also received high gene expression–based scores, driving
a slight enrichment (about 1.1-fold over random sets of 396 drug
pairs, P¼0.164). Finally, although many drug pairs derived from
the synergistic EHR classes of lipid modifiers with drugs for obstruc-
tive airways also scored high based on gene expression, a large
number of drug pairs corresponding to these classes were not syn-
ergistic based on gene expression, resulting in no enrichment
(NES<1, Figure 4C).
Therefore, for 2 out of 3 EHR-based synergistic drug class pairs,
NES>1 suggests that these pairs also tended to be high scoring
based on breast cancer gene expression association. Furthermore,
the molecular networks comprising gene expression, drug-protein,
and protein-protein interactions used to derive gene expression–
based scores provide mechanistic hypotheses for the observed syner-
gism of the EHR-based pairs. These pairs are also supported by pre-
clinical and epidemiologic studies. The third drug class pair
discovered using EHR (lipid modifiers and drugs for obstructive air-
ways) was not enriched among gene expression–based pairs. As this
study focuses on synergistically beneficial interactions, we will only
discuss in detail the 2 synergistically beneficial drug class pairs un-
covered by both EHR and gene expression data.
Synergistically beneficial pair 1: anti-inflammatory
agents and lipid modifiers
Drugs belonging to the first pair of synergistic drug classes identified
using EHR data (anti-inflammatory agents, especially NSAIDs,
paired with lipid modifiers, especially statins) have been proposed as
a general regimen for chemoprevention.43 While no benefit specifi-
cally against breast cancer has been reported for this combination,
there is a growing body of epidemiological evidence supporting a
synergistic anticancer benefit of NSAIDs with statins, especially
against colorectal and prostate cancer.43–46 In addition, preclinical
studies suggest plausible anticancer mechanisms of these drugs indi-
vidually, with NSAIDs functioning as aromatase inhibitors and the
inhibitory effects of statins on breast cancer cell growth and prolifer-
Table 1. continued
Patient Characteristic Cases/Dead (n¼ 1212) Controls/Alive (n¼ 8733) Total (n¼ 9945)
N or mean % or SD N or mean % or SD N or mean % or SD
Diabetes (uncomplicated) 25 2% 44 0.5% 69 0.7%
Diabetes (complicated) <10 0.7% <10 0.09% 17 0.2%
Plegia <10 0.0% <10 0.03% <10 0.03%
Renal disease 17 1.4% <10 0.1% 26 0.3%
Malignancy 286 24% 1584 18% 1870 19%
Metastasis 61 5% 57 1% 118 1%
HIV <10 0.4% 10 0.1% 15 0.2%
Charlson Comorbidity Scorea 2.4 2.6 1.1 1.4 1.2 1.7
aAt: time of diagnosis; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; TNBC: triple-negative
breast cancer.
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ation.43,47,48 It has been suggested that, in combination, NSAIDs
and statins inhibit cell growth and promote apoptosis, possibly by
inducing the tumor suppressor RhoB and inhibiting the Akt path-
way, key targets in tumorigenesis.43,49
Using our breast cancer network model, we identified frequent pro-
tein interactions with this pair of drug classes that corroborate this epi-
demiological and preclinical evidence (Supplementary Table S4). Both
transcription factor AP-1 (which interacts with several anti-inflamma-
tories/antirheumatics50 and sequence CCAAT/enhancer-binding pro-
tein beta (which interacts with several lipid modifiers) influence breast
cancer cell senescence and apoptosis.51,52 A drug combination that tar-
gets these proteins simultaneously may therefore elicit stronger effects
on cell death or proliferation.
Drug synergism could also be achieved when one drug influences
the efficacy of a second drug. For example, expression levels of insu-
lin receptor substrate 1 (which interacts with several anti-
inflammatory/antirheumatic drugs,53 can predict patient responses
to chemotherapeutic or hormonal breast cancer therapies.54,55
Inhibiting AP-1 also potentiates hormonal therapies.56 These associ-
ations suggest that proteins targeted by anti-inflammatory agents
may participate in synergistic combinations with hormone antago-
nists (see below) and possibly other anticancer therapies.
Synergistically protective pair 2: anti-inflammatory
agents and anticancer hormone antagonists
While anti-inflammatory drugs are known to help patients better
tolerate hormone therapy’s undesirable side effects until endocrine
responsiveness is elicited, there is evidence in the literature suggest-
ing joint anticancer action between anti-inflammatory agents and
hormone antagonists. Many anti-inflammatories inhibit
cyclooxygenase-2, which in turn inhibits aromatase that is otherwise
required for estrogen production.47,57–59 By combining a
cyclooxygenase-2 inhibitor (NSAID or coxib) with a hormone an-
tagonist like an aromatase inhibitor, synergistic regulation of hor-
mone production may halt or slow mammary tumorigenesis.59,60
Clinical trials have shown that the combination of celecoxib and
exemestane is slightly better or equivalent to exemestane monother-
apy.59,61 Benefits include longer periods of stable disease (tumor
shrinkage or no new lesions)59 and reduced tumor expression of
proliferation-associated genes.61 However, the increased cardiovas-
cular risk associated with celecoxib has raised concerns about its
risk-benefit ratio.
Although synergistic pairs of anti-inflammatory/antirheumatic
agents and hormone antagonists were only slightly enriched among
all synergistic pairs identified based on gene expression, analysis of
proteins that frequently interact with drugs in these classes suggests
possible molecular mechanisms to explain their observed synergy
(Supplementary Table S5). For example, genetic knock-down of
caveolin-1, which interacts with several anti-inflammatory drugs,
renders breast tumors hypersensitive to estrogen.62,63 Simultaneous
inhibition of caveolin-1 may therefore enhance the efficacy of
antiestrogen therapies. Another protein linked to multiple anti-
inflammatory drugs, tristetraprolin, interacts with progesterone,
estrogen, and androgen receptors.64 Reducing protein levels of
tristetraprolin in breast cancer cell lines augments hormonal ef-
fects on cell growth and proliferation, possibly rendering cells
more sensitive to hormone antagonist therapies.65 These molecu-
lar links could support the predicted synergistic efficacy of anti-
inflammatory/antirheumatic drugs and hormone antagonists in
breast cancer treatment.
Study limitations
We acknowledge that the effect sizes of the synergism discussed
above are small (beta coefficients of interaction terms: 0.004–0.05)
despite statistical significance (P<0.05) in EHR and enrichment in
molecular data and supporting evidence from the literature. Some of
the drug pairs discovered (Figure 3 and Table 2) may represent in-
tentional concurrent usage rather than actual mechanistic synergism.
Disambiguating between the 2 is challenging when using observa-
tional data, as the intent is not stated. For example, deliberate con-
current use may be in order to overcome resistance to a single
therapy or to relieve side effects (eg, venlafaxine to improve toler-
ance to aromatase inhibitors) or to treat coincidental conditions (eg,
Figure 2. Odds ratios of factors (excluding pairwise interactions) most associ-
ated with 5-year mortality (see also Supplementary Table S3).
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venlafaxine for psychological distress, prevalent in 30–50% of
breast cancer patients66).
Nevertheless, one key advantage of our approach of formulating
pairwise interaction effects is the simultaneous discovery of multiple
interaction effects. This generates multiple hypotheses for in-depth
evaluation by drug screening in cell lines and animal models, as well
as by subsequent observational studies and clinical trials. Our ap-
proach also discovered synergistically adverse drug pairs (ie, adverse
drug-drug interactions, Figure 3), which we did not discuss in detail,
given our focus here on the synergistically beneficial ones that could
potentially be repurposed. One disadvantage is the risk of false dis-
coveries, especially when correlated pairs could be falsely detected
as interaction effects. To minimize false discoveries, we boot-
strapped samples and reran our models 500 times to empirically
generate 95% CI, in an attempt to address the variance associated
with the beta estimates but not necessarily the bias inherent in penal-
ized regressions such as glinternet.67 While there are sophisticated
bootstrapping procedures designed to reduce the bias, estimating the
CIs for penalized regression remains an active area of research.68
The purported breast cancer benefit of metformin could also be
used as a positive control for testing our method on monotherapy
drugs.1,10,47 Metformin, on its own, was not associated with lower
mortality. We did, however, find a borderline benefit (Hazard
ratio: 0.86 [0.52–1.00]) in a separate lasso Cox regression survival
Figure 3. Variables (nodes) that synergistically interact such that they are associated with lower mortality (blue edges) or higher mortality (red edges, also see
Table 2). Variable nodes that tend to have synergistically beneficial interactions (blue edges) also tend to be factors associated with lower mortality (eg, Stage I),
while those with synergistically risky interactions (red) tend to be risk factors on their own (eg, Stage IV). Nodes are grouped together (eg, by categorical level,
ATC class) to facilitate visual comparison within a group (eg, Stages I and II have many synergistically beneficial interactions while Stages III and IV have many
synergistically risky interactions). Case studies described in the Discussion section are highlighted with thicker edges.
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analysis without pairwise interactions (Supplementary Table S6).
While a Cox regression model with the same overlap group lasso
(as used in glinternet here) was an attractive alternative, the cur-
rent implementation of glinternet supports only logistic regression.
A survival analysis setup with time-varying exposures could also
account for the temporal sequence of the drug exposures, which
was not considered here. However, Cox regression models are
prone to time-dependent biases (eg, immortal bias), and some stud-
ies have indeed questioned whether metformin’s benefit could have
arisen from such biases.10
Patients might also have received care, including the drugs stud-
ied, outside of Stanford Hospital and PAMF. Such instances and
other supporting information, undocumented in our data source,
may result in unmeasured confounding, a known limitation of EHR-
based studies.69 Nevertheless, we tried to obtain the most compre-
hensive clinical details possible in our choice of Oncoshare, which
links EHRs from Stanford University and the neighboring PAMF
community health service with the California Surveillance, Epidemi-
ology, and End Results Program registry and other supporting ser-
vices such as Oncotype DX.22,70
Another limitation is the use of predefined drug classes, which
may be overly broad and heterogeneous (eg, drugs for obstructive
airways, R03). We repeated the analysis (Supplementary Table S7),
aggregating drugs to ATC drug classes of various granularities and
pair 1 between anti-inflammatory agents and, in particular, aroma-
tase inhibitors was replicated. On the other hand, overly specific
subclasses containing rarely used drugs may also pose problems, as
we did not always observe synergism among the more granular sub-
classes (Supplementary Table S7).
Our molecular analysis was limited primarily by gene expression
and drug data availability. In terms of gene expression, only 14 data-
sets were of sufficient quality and contained appropriate case and
Table 2. Synergistic drug pairs discovered
Overall ER or PR without HER2 expression HER2 expression TNBC
Nasal_preparationsþ lactate
hormone antagonists and
related agentsþ vitamins
anti-inflammatory and
antirheumatic productsþ
lipid_modifying_agents
drugs_for_obstructive_
airway_diseasesþ
lipid_modifying_agents
hormone_antagonists_and_
related_agentsþ anti-
inflammatory _and_anti-
rheumatic_products
Tretinoinþ epinephrine
ondansetronþ pantoprazole
tazobactamþ lansoprazole
lidocaineþ atropine
hydrocodoneþ ondansetron
anti-estrogensþ ondansetron
aromatase_inhibitorsþ granisetron
mupirocinþ ergocalciferol
naloxoneþ heparin
glucoseþ aspirin
meperidineþ glucose
hydrocodoneþ glucose
anti-metabolitesþ glucose
cephalexinþ hydrochlorothiazide
fentanylþ hydrochlorothiazide
nitrofurantoinþ lisinopril
celecoxibþ losartan
tretinoinþ clobetasol
meperidineþ dexamethasone
fentanylþ dexamethasone
tretinoinþ phenazopyridine
letrozoleþ amoxicillin
hydrocodoneþ amoxicillin
anti-metabolitesþ cephalexin
naloxoneþ cefazolin
celecoxibþ tretinoin
glycopyrrolateþ tretinoin
neostigmineþ propofol
hydrocodoneþ bupivacaine
lidocaineþ bupivacaine
naloxoneþ fentanyl
iso_sulfan_blueþ fentanyl
acetic_acid_derivatives_and_related_
substancesþ fentanyl
ciprofloxacinþ guaifenesin
naloxoneþ hydrocodone
nitrogen_mustard_analoguesþ
hydrocodone
lactateþ simethicone
docusateþ simethicone
Heparinþ famotidine
rocuroniumþ aprepitant
acetaminophenþ prednisone
venlafaxineþ atorvastatin
morphineþ promethazine
trazodoneþ promethazine
hydrocodoneþ promethazine
cefazolinþ dexamethasone
immunostimulantsþ
dexamethasone
colony_stimulating_factorsþ
dexamethasone
escitalopramþ clindamycin
venlafaxineþ clindamycin
propofolþ estradiol
venlafaxineþ estradiol
rocuroniumþ estradiol
propofolþ phenazopyridine
bupivacaineþ phenazopyridine
escitalopramþ phenazopyridine
mometasoneþ phenazopyridine
neostigmineþ phenazopyridine
rocuroniumþ phenazopyridine
acetaminophenþ doxorubicin
escitalopramþ propofol
venlafaxineþ propofol
mometasoneþ propofol
escitalopramþ bupivacaine
venlafaxineþ bupivacaine
olopatadineþ bupivacaine
mometasoneþ bupivacaine
desonideþ bupivacaine
neostigmineþ bupivacaine
anti-estrogensþ acetaminophen
venlafaxineþ escitalopram
neostigmineþ escitalopram
olopatadineþ venlafaxine
mometasoneþ venlafaxine
desonideþ venlafaxine
neostigmineþ venlafaxine
rocuroniumþ olopatadine
neostigmineþmometasone
neostigmineþ desonide
Fentanylþmetoclopramide
metronidazoleþ hydrochlorothiazide
naproxenþ simvastatin
valacyclovirþ simvastatin
venlafaxineþ simvastatin
fluticasoneþ simvastatin
rocuroniumþ simvastatin
doxorubicinþ dexamethasone
estradiolþ naproxen
valacyclovirþ naproxen
fluticasoneþ naproxen
fluticasoneþ estradiol
anti-inflammatory and anti-rheumatic_
productsþ sulfamethoxazole
fluticasoneþ azithromycin
venlafaxineþ valacyclovir
mometasoneþ valacyclovir
rocuroniumþ valacyclovir
hydrocodoneþ acetaminophen
fluticasoneþ venlafaxine
thyroxineþmometasone
rocuroniumþmometasone
rocuroniumþ fluticasone
aromatase_inhibitorsþ rocuronium
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control samples for differential gene expression analysis. This pre-
cluded us from performing separate meta-analyses of breast cancer
molecular subtypes. Information on drugs is similarly limited to
those with reported protein interactions, which may be additionally
restricted to anticipated interactions based on a drug’s class and ap-
proved indications. For example, many specific pairs of EHR-based
synergistic drugs lack reported protein interaction information in
DrugBank, but have protein interaction information in DrugBank at
the drug class level. Although DrugBank is one of several widely
used sources of drug information,71 alternate sources could have
been explored. Similarly, protein-protein interactions may not be
fully documented or validated, or may vary in their biological rele-
vance (eg, some interactions were discovered in yeast 2-hybrid as-
says that are less relevant to breast cancer pathology). Despite these
limitations, gene expression–based ranking of synergistic drug pairs
provides an alternative data source to validate pairs discovered from
EHRs. The consistency of the results from multiple data sources and
analysis methods should increase the robustness of our findings.
CONCLUSIONS AND IMPLICATIONS
This is a proof-of-concept study demonstrating that searching for
statistical interactions can discover drug pairs that moderate each
other’s effects. Such an approach has also been used to discover epi-
static interactions among genes.26,72 Much of the published litera-
ture on drug interactions has focused on adverse drug-drug
interactions instead of potentially beneficial interactions for drug
repurposing. Here, we report 3 synergistically therapeutic pairs of
drug classes associated with lower 5-year mortality in patients with
breast cancer. Of the 3 synergistically protective pairs, 2 were sup-
ported by analysis of gene expression data of breast cancer patients,
biological plausibility, preclinical models, and epidemiologic evi-
dence in the literature. The glinternet analysis of EHRs we presented
is scalable to drug combinations of 2 or more. As demonstrated,
coupling with orthogonal analysis of gene expression data can cor-
roborate the EHR-based findings and reveal protein interactions
that may relate to the mechanism driving drug synergism. This study
further demonstrates the translational potential of existing data
sources such as real-world patient EHRs and gene expression data-
bases. The multidrug combinations uncovered can be computation-
ally prioritized to help direct preclinical research and, if promising,
undergo clinical trial validation, repurposing, and optimizing of ex-
isting drugs for maximum therapeutic benefit.
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